Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Schrodinger","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics and Schr\u00f6dinger Collaborate to Discover Novel Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Begins Dosing in Phase I\/II Solid Tumours Therapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$496.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$4,000.0 million","newsHeadline":"Takeda to Acquire Nimbus Therapeutics\u2019 Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$4,000.0 million","newsHeadline":"Takeda Completes Acquisition of Nimbus Therapeutics\u2019 TYK2 Program Subsidiary","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Anagenex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Nimbus Therapeutics

    Menu

    Nimbus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nimbus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

              Details:

              NDI-101150, a small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) which is under phase 1/2 clinical development for the treatment of solid tumors.

              Lead Product(s): NDI-101150

              Therapeutic Area: Oncology Product Name: NDI-101150

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications

              Details:

              Under the collaboration, Anagenex and Nimbus will discover small molecule drugs for multiple challenging targets by applying Anagenex’s AI driven parallel biochemistry platform to generate experimentally measured datapoints for each of Nimbus’ nominated targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Anagenex

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines

              Details:

              Nimbus will use financing to continue the ongoing clinical development of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors.

              Lead Product(s): NDI-101150

              Therapeutic Area: Oncology Product Name: NDI-101150

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Google Ventures

              Deal Size: $210.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement September 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

              Details:

              Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. This acquisition strengthens Takeda’s growing late-stage pipeline and potentially expands its portfolio and patient impact across multiple indications.

              Lead Product(s): NDI-034858

              Therapeutic Area: Immunology Product Name: TAK-279

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Takeda Pharmaceutical

              Deal Size: $6,000.0 million Upfront Cash: $4,000.0 million

              Deal Type: Agreement February 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases

              Details:

              The acquisition strengthens Takeda's autoimmune portfolio, preferably NDI-034858 candidate, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases, especilally moderate to severe plaque psoriasis.

              Lead Product(s): NDI-034858

              Therapeutic Area: Immunology Product Name: NDI-034858

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Takeda Pharmaceutical

              Deal Size: $6,000.0 million Upfront Cash: $4,000.0 million

              Deal Type: Acquisition December 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis

              Details:

              NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therapeutic margins.

              Lead Product(s): NDI-034858

              Therapeutic Area: Dermatology Product Name: NDI-034858

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK

              Details:

              Nimbus’s computational drug discovery engine and expertise in structure-based drug design, Nimbus is uniquely positioned to develop isoform-selective small molecule activators of AMPK with potential therapeutic application to a broad range of metabolic disorders.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $496.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration October 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting

              Details:

              In a Phase 1 clinical study, NDI-034858 demonstrated a good tolerability profile and evidence of clinical and pharmacodynamic activity across multiple measures of disease pathology in psoriasis.

              Lead Product(s): NDI-034858

              Therapeutic Area: Dermatology Product Name: NDI-034858

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting

              Details:

              The pharmacokinetic profile of NDI-034858 observed in healthy volunteers supports the potential for once-daily dosing, with 50 mg expected to cover IC90 for 24 hours.

              Lead Product(s): NDI-034858

              Therapeutic Area: Dermatology Product Name: NDI-034858

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nimbus Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting

              Details:

              NTX-801, a Casitas B-lineage lymphoma b inhibitor demonstrated strong immune cell activation and robust and statistically significant tumor growth inhibition in a mouse syngeneic tumor model.

              Lead Product(s): NTX-801

              Therapeutic Area: Oncology Product Name: NTX-801

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY